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Abstract
Current efforts in the biomedical sciences and related interdisci-
plinary fields are focused on gaining a molecular understanding of
health and disease, which is a problem of daunting complexity that
spans many orders of magnitude in characteristic length scales, from
small molecules that regulate cell function to cell ensembles that form
tissues and organs working together as an organism. In order to un-
cover the molecular nature of the emergent properties of a cell, it is
essential to measure multiple cell components simultaneously in the
same cell. In turn, cell heterogeneity requires multiple cells to be
measured in order to understand health and disease in the organism.
This review summarizes current efforts towards a data-driven frame-
work that leverages single-cell technologies to build robust signatures
of healthy and diseased phenotypes. While some approaches focus
on multicolor flow cytometry data and other methods are designed
to analyze high-content image-based screens, we emphasize the so-
called Supercell/SVM paradigm (recently developed by the authors of
this review and collaborators) as a unified framework that captures
mesoscopic-scale emergence to build reliable phenotypes. Beyond their
specific contributions to basic and translational biomedical research,
these efforts illustrate, from a larger perspective, the powerful synergy
that might be achieved from bringing together methods and ideas from
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statistical physics, data mining, and mathematics to solve the most
pressing problems currently facing the life sciences.
1 Introduction
Single-cell heterogeneity poses a huge challenge in the development and im-
provement of strategies for the diagnosis and treatment of many diseases.
Indeed, it is a well-established fact that cells from the same tissue display
significant qualitative and quantitative heterogeneities, even within samples
obtained from a single individual. This inherent biological diversity has com-
plicated efforts to capture the essence of health and disease in terms of charac-
teristic behaviors at the single-cell level and has, therefore, limited our ability
to fully take advantage of new single cell analysis approaches to improve the
current practice of personalized medicine.
For instance, Beckman et al. [1] have very recently assessed the impact of
single-cell heterogeneity, as well as that of genetic instability, in the develop-
ment of effective nonstandard strategies for personalized cancer treatment.
Manifestations of cell heterogeneity in healthy and diseased cell samples have
ubiquitously been reported in the growing field of single-cell biology, ranging
from human pluripotent embryonic stem cell cultures [2, 3, 4] and apoptosis
mechanisms in cancer cell lines [5], to reversible adaptive plasticity in tumors
such as human neuroblastoma [6] and pressure-driven shape features of C.
elegans embryonic cells [7]. For recent reviews of the impact of tumor hetero-
geneity at different levels (genetic, epigenetic, the tumor microenvironment,
the immune response, and other factors such as diet and the microbiota), see
Refs. [8, 9, 10, 11].
The difficulties of pinpointing specific characteristics of different healthy
and diseased cell subpopulations prompted the development and refinement
of experimental techniques that allow multidimensional measurements on
single cells, such as e.g. multicolor flow cytometry [12, 13, 14], high perfor-
mance kinetic image cytometry [15], and the very recently introduced mass
cytometry (CyTOF) technique [16, 17, 18]. Certainly, the improvement of
these experimental methods allows one to probe single cells in increasingly
high-dimensional parameter spaces, which in turn enhances the resolution to
identify and focus on specific cell subpopulations. As the experimental tech-
niques evolve, however, the pressing need for improving our ability to process
and analyze “Big Data” in the life sciences becomes increasingly manifest. In
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fact, we need unbiased, mathematically robust, scalable methods that allow
us to identify the key parameters that consistently characterize cell subpop-
ulations across different samples in order to build signatures of health and
disease across length scales spanning many orders of magnitude [19].
In this review, we summarize current data-driven efforts that leverage
single-cell technologies to build robust signatures of healthy and diseased
phenotypes. We focus on two key types of single-cell datasets, namely multi-
color flow cytometry, in which each cell is characterized by a set of up to 20
measurements corresponding to scattering and fluorescent emission of light
upon stimulation by laser beams, and microscopy via high-content image-
based screens, in which multiple parameters characterize the shape of each
cell, often used in combination with biomarker intensity measurements. In
Section 2, we discuss the challenges arising from biological complexity, emer-
gent phenomena, and cell heterogeneity. In Section 3, we review efforts to
build phenotypes based on flow cytometry data analysis techniques. In Sec-
tion 4, we summarize profiling methods for microscopy image-based screens.
In Section 5, we present the Supercell/SVM paradigm, which is a general
approach for emergent phenotyping that can be applied to different kinds
of single-cell datasets, including multicolor flow cytometry and cell imaging.
Finally, in section 6, we present our concluding remarks.
2 From Molecules to Cells to Organisms:
Complexity, Emergence, and the Cell
Heterogeneity Challenge
Certainly, gaining a molecular understanding of disease is the holy grail of
current biomedical research and related interdisciplinary fields. The com-
plexity of this problem, however, is daunting; from a physical perspective,
this complexity arises from the plethora of scales, the great diversity of sys-
tem components, and the sheer size of biological systems. Indeed, a human
being is a hierarchically organized, multiscale system that spans about 10 or-
ders of magnitude in relevant length-scales, from water molecules (0.2 nm),
DNA molecules (2.5 nm) and proteins (typically 2-10 nm) to cells (10-100
µm), tissues, organs, and organ systems. Besides the multi-scale nature of
the problem, complexity arises from the high dimensional variety of subtypes
(e.g. about 300 human cell types and 25000 protein-coding genes) and the
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astonishingly large system size (e.g. 3 × 109 DNA base pairs contained in
each one of the 10-100 trillion cells of a human being).
Physics is familiar with the concept of emergence, that is, the collective,
large-scale generic behavior of a system that manifests itself independently of
small-scale details [20]. In macroscopic systems, thermodynamics and statis-
tical mechanics provide the theoretical framework to understand macroscopic
emergence, which explain large-scale phenomena such as ferromagnetism and
irreversibility. At mesoscopic scales, however, other kinds of emergent behav-
ior may arise out of as yet unknown physical laws [21]. Collisions of macro-
scopic particles in low concentration granular suspensions, for instance, tend
to disrupt the inherent reversibility of low Reynolds number fluid flows [22],
and the onset of irreversibility decreases approximately as the square of par-
ticle density. In dense granular systems under cyclic shear, rearrangements in
dense configurations are highly collective and known to exhibit reversibility
of the neighbor topology in mesoscale trajectories [23]. In biophysics, emer-
gence and complexity are often tackled through multi-scale modeling, which
is focused on determining the relevant scales involved in specific processes of
interest, as for instance coarse-graining lipid self-assembly dynamics [24, 25]
and actin filament networks [26, 27], as well as using information theory to
predict and measure the amount of information transduced by molecular and
cellular networks [28].
Compounding the multifaceted challenges of emergence and complexity,
biological processes are often highly heterogeneous [29]. State-of-the-art
technologies, ranging from multicolor flow cytometry and mass cytometry
to imaging and single-cell gene expression profiling, are now allowing us to
measure multiple properties on single cells. The emerging picture from this
growing body of single-cell data shows us that cell heterogeneity is ubiqui-
tous. Fig. 1 illustrates the manifestation of cell heterogeneity in different
kinds of single-cell datasets. In Fig. 1(a), 100 CD8+ T cells per patient have
been randomly sampled from a cohort of 7 patients diagnosed with sarcoido-
sis and 6 patients diagnosed with Behc¸et’s disease, two autoimmune diseases
with very similar clinical manifestations. The cells have been stained with 14
fluorochromes; together with forward- and side-scattering, 16 measures have
thus been performed on each cell. Despite single-cell flow cytometry data
being high dimensional, it is common practice to perform sequential manual
partitioning (so-called “gating”) of cell events through visual inspection of
scatter plots in 2D. Despite the fact that the two markers chosen, CD3 and
IL22, are the top markers in a multi-parametric phenotype designed to opti-
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Figure 1: (a) 2D scatter plot of CD8+ T-cell flow cytometry samples from
a cohort of 7 patients diagnosed with sarcoidosis and 6 patients diagnosed
with Behc¸et’s disease, two autoimmune diseases with very similar clinical
manifestations. Highly overlapping cell populations (shown as a function
of the intensity of fluorochrome stains for markers CD3 and IL22) are the
hallmark for the phenomenon of cell heterogeneity. (b) Nuclear shapes of
diseased ((i) and (ii)) and healthy ((iii) and (iv)) cells can be classified as
either blebbed ((i) and (iii)) or non-blebbed ((ii) and (iv)). The diseased
nuclei are from Hutchinson-Gilford Progeria Syndrome (HGPS) cell lines.
Scale bar: 10 µ. Adapted from Ref. [30].
mally separate these two diseases (see Fig. 6(b)), these cell populations are
highly overlapping. Similar overlaps are also observed for other cell types and
marker pairs. In Fig. 1(b), images of cell nuclei from a cell line classified as
Hutchinson-Gilford Progeria Syndrome (HGPS), a premature aging disorder,
are compared to healthy cells. HGPS is known to be caused by mutant lamin
A, which affects the nuclear scaffolding; the phenotypic hallmark of HGPS
is nuclear blebbing [31]. Due to cell heterogeneity, however, we observe both
blebbed (i) and non-blebbed (ii) diseased cells, and similarly, blebbed (iii)
and non-blebbed (iv) normal cells.
There are multiple potential mechanisms for the heterogeneity in cell
shape. In addition to the heterogeneity in protein expression levels, molecu-
lar mechanisms for intracellular transport are also known to be highly het-
erogeneous [32, 33]. These transport mechanisms can be broadly classified
into two categories: passive diffusion and motor-driven active transport. By
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performing extensive single-tracking microscopy of endogenous lipid gran-
ules in living fission yeast cells, it has been shown that the granules exhibit a
crossover behavior from continuous time random walk subdiffusion at short
time scales to subdiffusive fractional Brownian motion at longer times [34].
The associated phenomenon of weak ergodicity breaking leads to the observed
crossover in the measured mean squared displacements [34]. Very recently,
other scenarios based on heterogeneous diffusion, in which the diffusion co-
efficient depends on the particle position within the cell, have been explored
as well also showing that they lead to sub- and super-diffusive regimes with
weak ergodicity breaking [35, 36, 37]. In the case of active transport, a variety
of stochastic approaches have been proposed to explain in vivo intracellular
observations of tracked biomolecules and microbeads including random walk
models, quasi-steady-state reduction methods, exclusion processes, random
intermittent search processes, Brownian ratchets, along with mean-field ap-
proximations (see [32, 33] and references therein).
The interplay of complexity, emergence, and cell heterogeneity poses a
huge challenge to build reliable molecular phenotypes of disease. In the
following Sections, we briefly summarize current data-driven efforts based
on flow cytometry and cell imaging, although some of those approaches may
also be applied to other kinds of state-of-the-art and forthcoming single-cell
techniques, such as mass cytometry CyTOF), single-cell gene expression, and
single-cell full genome sequencing technologies.
3 Single-cell-based Phenotyping using
Multicolor Flow Cytometry Data
Flow cytometry is used routinely both in research labs to investigate cell
structure and function as well as in clinical labs to diagnose disease, assess
its progression and its response to therapy. The flow cytometry technique
is based on fluorochrome-conjugated antibodies that attach to cell surface
proteins and intracellular molecules. Laser beams and detectors are used
to measure the forward-scattered light (which provides a measurement of
the size of the cell), the side-scattered light (which is used to determine the
internal structures within the cell) and the emitted light from each type of
fluorochrome (which is proportional to the corresponding antigen density).
By using compensation techniques to resolve the overlaps of absorption and
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emission spectra, up to 20 different properties can be determined on a cell-
by-cell basis [38, 39].
Although single-cell flow cytometry data is high dimensional, practition-
ers usually perform sequential manual gating of cell events through visual
inspection of scatter plots in 2D, a procedure aided by a number of anal-
ysis software programs such as FlowJo [40] and FCS Express [41]. Over
the past few years, new computational methods have been developed in
order to overcome the serious limitations in manual gating-based analy-
sis [42, 43, 44, 45, 46, 47, 48, 49]. All these methods share a common rationale,
which is first to define a procedure to extract characteristic features from each
sample, and then to perform machine-learning-based classification of different
sample types. A comparative assessment of the performance and accuracy
of different methods is summarized in Ref. [50]. Typically, machine-learning
instance space is defined by statistical population measures (such as mean,
standard deviation and higher moments), histogram classification (through
binning into low-dimensional measurement subsets), clustering of events (e.g.
k-means or spectral clustering) or mixture models (Gaussian, nonparametric
Bayesian, skew-t, etc). Since flow cytometry is high-throughput, with sam-
ples typically consisting of hundreds of thousands and even millions of cells,
some methods incorporate down-sampling preprocessing steps. In particular,
density-based down-sampling methods are designed to filter out denser re-
gions, so that small subpopulations of cells are more significantly represented
in the down-sampled datasets than in the original data.
For the purpose of illustration, we summarize here one particular ap-
proach that has successfully been applied to classifying acute myeloid leukemia
(AML) positive patients and healthy donors using flow cytometry data [46],
which is based on the so-called SPADE algorithm [51] that has also proved
useful in cell subpopulation analysis of mass-spectroscopy-based cytome-
try [17]. First, SPADE is applied to perform the extraction of features based
on the relative size of subpopulations. SPADE consists of four computa-
tional modules: density-dependent down-sampling, agglomerative clustering,
minimum-spanning tree construction, and up-sampling. Using data from all
samples (both diseased patients and healthy donors), a tree formed by 150
clusters was obtained. It is assumed that groups of clusters roughly corre-
spond to different cell subpopulations. Second, the distribution of cells across
the 150 clusters is computed for each sample. Fig. 2(a) shows the cell distri-
bution across the SPADE tree for a healthy donor, while Fig. 2(b) displays
the cell distribution for a diseased patient. Third, the pairwise Earth Mover’s
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Figure 2: Cell distribution of different cell subpopulations in the SPADE
tree for (a) one healthy donor and (b) one AML patient. (c) Pairwise EMD
distance between training samples, where the order of the samples in the
heat-map was organized by hierarchical clustering. The bottom panel shows
the class label of each training sample, green for healthy and red for diseased.
(d) Relief scores to predict test samples. Adapted from Ref. [46].
Distance (EMD) between cell distributions is calculated. EMD measures the
minimum effort needed to make one distribution the same as the other by
moving cells, which can be calculated as a constrained linear programming
problem [52]. Pairwise EMDs for all training samples (156 healthy donors
and 23 diseased patients) are shown in Fig. 2(c), where the order of the sam-
ples in the heat-map was organized by hierarchical clustering. The bottom
panel shows the class label of each training sample, green for healthy and red
for diseased. Finally, test samples were classified based on their Relief scores.
Relief is a nearest neighbor based classifier [53]; the Relief score for one test
sample is defined as the distance (which, in this case, is determined using the
EMD metric) between the test sample and the nearest normal sample minus
the distance from the test sample to the nearest AML sample. Therefore, test
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Figure 3: Multiparameter automated feature extraction from nuclei imaging.
In this example, after variations in illumination and staining are corrected,
nuclei are identified by thresholding and then used as seeds to identify cell
edges. Finally, markers are used to identify DNA-damage foci. Multipara-
metric quantitative single-cell features may then result from transformations
of the image-based measurements. From Ref. [57].
samples with negative Relief scores are classified as normal, whereas samples
with positive Relief scores are classified as diseased. Fig. 2(d) shows blind
test results for 180 samples ordered from left to right by increasing Relief
scores. As it turns out, all the samples with positive Relief scores have been
correctly classified as diseased. This procedure can be straightforwardly ex-
tended to the case in which multiple test tubes are used to measure different
sets of fluorochromes [46].
4 Single-cell-based Phenotyping using
Microscopy Images
The field of biological image analysis has seen rapid progress with the ad-
vent of automated image acquisition systems that enable new types of mi-
croscopy experiments. A variety of imaging techniques yield high-content,
high-throughput images from fluorescence microscopy, electron microscopy,
bright-field microscopy, differential-interference-contrast microscopy, as well
as from multi-spectral and multi-dimensional microscopy. Yet, the bottle-
neck for progress in this field appears to lie in the efficacy of computer vision,
image analysis, and pattern recognition methods [54].
The analysis of digital microscopy images usually requires identifying so-
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called “regions of interest” (ROIs), e.g. cells, cell nuclei or organelles that
represent target objects within the images. The process of ROI identifica-
tion is still sometimes performed manually; this approach, however, is labor-
intensive and impractical for the analysis of large-scale screens, and is prone
to introducing procedural biases and inconsistencies. In computer-aided im-
age analysis, the first step is usually to determine ROIs and disentangle fore-
ground from background pixels, a process known as segmentation, although
pattern recognition can also be used to process whole images or image tiles
on a grid without identifying ROIs [55, 56]. Fig. 3 illustrates the process
of ROI definition and extraction in a fluorescence-microscopy image of cul-
tured cells from screens. In this example, the goal is to segment individual
nuclei and individual DNA-damage-induced foci, as well as to segment the
cells to characterize their individual morphology. To this end, a set of three
fluorescent stains (DNA, cytoplasm, and DNA-damage markers) are used
and recorded in each image in different channels. Some implementations
of segmentation algorithms are designed for a very specific type of object
(e.g. 3 − D images of neurons [58]) and hence do not require detailed fit-
ting of parameters, while other tools are of a more general scope and need
more intensive tuning to target the desired ROIs. Widely used methods in-
clude global thresholding [59, 60] with or without bias correction [61], local
or adaptive thresholding [62], segmentation based on texture, local intensity
variations or other features [63], watershed algorithms [64, 65, 66, 67], model-
based segmentation [68], level-set approaches [69], contour methods [70, 71],
and automatic edge detection [72].
After the identification of Regions of Interest, the process continues by ex-
tracting image content descriptors, see Fig. 4. Feature extraction algorithms
read image pixels from foreground ROIs and output a variety of numerical
image features that characterize the assay, including the number of objects
per image (e.g. the number of DNA-damage-induced foci per cell in the ex-
ample from Fig. 3), the intensity of a marker as reflected by pixel intensity
in a given channel (e.g. the total intensity of DNA marker in the nucleus
can be used to identify cell-cycle phases), texture descriptors (such as statis-
tical, structural, and spectral texture measures), and shape descriptors that
enable morphological phenotyping (e.g. Zernicke shape features [74] and Hu
moments [75]). In some applications, image features are extracted from ar-
bitrarily defined tiles that do not necessarily correlate with actual cellular or
subcellular features, which is the kind of approach used in algorithms such
as PhenoRipper [56] and WND-CHARM [76].
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Figure 4: Process of pattern recognition in biological image analysis: identifi-
cation of Regions of Interest, extraction of image content descriptors, feature
selection and classification, testing on new instances (or, alternatively, leave-
one-out cross-validation) and evaluation of results. From Ref. [73].
Finally, phenotyping healthy vs diseased samples, or chemically and ge-
netically perturbed samples, is usually achieved by implementing a machine
learning classifier. As shown schematically in Fig. 4, this process is iterative.
The initial set of features usually ranges between few tens and one hundred,
although it is assumed that many of them are irrelevant or redundant. Two
general approaches to feature selection are known as filters and wrappers [77].
Filtering methods are based on statistical measures before the classifiers are
applied. For instance, Fisher scores, which measure inter-class variance rela-
tive to intra-class variance, can be used to weight features according to their
classification discriminative power [76]. Another filtering approach, which
aims at avoiding the bias due to highly correlated features, is the so-called
minimum redundancy maximum relevance (mRMR) algorithm [78]. Other
filtering methods are based on remapping the original feature space into
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lower dimensional ones, including linear approaches such as singular value
decomposition [79, 80, 81] and principal component analysis [82, 83], as well
as non-linear ones such as self-organizing maps [84, 85], isomap [86], local
linear embedding [87] and multidimensional scaling [88, 89]. Wrapping ap-
proaches, in turn, select features based on their actual performance in the
classifier (see e.g. [77, 90, 91]); they oftentimes provide better feature se-
lection and greater classification accuracy than filtering, although in most
cases wrapping is significantly slower because it relies on running many iter-
ations with different feature sets (as indicated by the dashed upwards arrow
in Fig. 4).
A number of proprietary and open-source software tools are available
to perform specific image analysis tasks such as segmentation, feature se-
lection and classification. Moreover, some packages integrate all the tasks
needed along the image analysis workflow. Software packages such as WND-
CHARM [76], CellProfiler [92], ImageJ [93], PSLID [94], Ilastik [95], and
BIOCAT [96] offer diverse capabilities in terms of graphic user interface,
3D−image analysis, machine learning classifiers, extensible algorithm plu-
gins, ROI detection, automatic comparison among algorithms, commercial
software requirements, and OS platform requirements.
5 Emergent Phenotyping via the
Supercell/SVM Paradigm
Flow-cytometry-based phenotyping methods (see Sect. 3 and references
therein) usually rely on the fact that typical cytometry experiments are able
to perform multidimensional single-cell measurements on tens and hundreds
of thousands, if not even millions, of cells. Therefore, single-cell-level het-
erogeneities such as those described in Sect. 2 are averaged out by means
of large population averages. High-content image-based phenotyping meth-
ods (see Sect. 4 and references therein), in turn, usually focus on pattern
recognition and classification of regions of interest, but typically disregard
cell-to-cell heterogeneities within a given phenotype.
Heterogeneity from cell to cell, however, is now recognized in many cases
not as noise, but as an important feature of many living systems that enables
adaptation to changing environmental conditions for a heterogeneous ensem-
ble, from bacterial persistence under antibiotic treatment [97, 98] to plasticity
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and functional diversity in the human brain [99]. Single-cell heterogeneity is
often encountered in biomedical basic and translational research, as well as
in the clinical realm, and leads to particular challenges for studies that are
based on a limited number of single cells. There are two overall constraints
that limit the number of analyzed cells. In some diseases, the number of
cells that can be collected is limited; for instance, diagnosis of intraocular
lymphoma is performed through difficult specimen collection procedures that
yield very low numbers of collected cells, typically in the range of ten to a
hundred cells [100]. In the field of stem cell research, identifying stem cell
phenotypes through flow cytometry cell sorting often relies on extremely rare
subpopulations. For instance, long-term hematopoietic stem cells (LT-HSCs)
identified via immunophenotypes such as Lin−Kit+Sca+CD34loFlt3− [101]
and SLAM [102] represent only about 0.0075% of the cells from whole bone
marrow specimens; thus, more than a million whole bone marrow cells need
to be extracted, stained with multiple fluorochromes and sorted in order to
yield about one hundred LT-HSCs. In early embryonic development studies,
e.g. at the stage of mouse early development when the founder population of
germline cells have just emerged, there are just about 30 primordial germ cells
in the embryo [103]. The second constraint is due to the analysis approach,
where more sophisticated analysis with a larger number of parameters (i.e.
higher dimensional data) usually are accompanied by lower numbers of cells
analyzed. Image based screens are typically based on tens to hundreds of
cells, with higher dimensional analyses (e.g. 3D cell shapes, multispectral
images) often based on fewer cells than simpler lower dimensional datasets.
State-of-the-art single-cell genomics technologies are an extreme example of
this trend. It is now possible to measure the expression level of all 20, 000+
genes in a single cell [104], but the number of cells for which all genes can be
measured is limited by both cost and instrument capacity. For these new high
dimensional data with limited numbers of datapoints, data analysis meth-
ods that rely on high-dimensional clustering procedures, Gaussian mixture
approximations, etc may be expected to fail.
Therefore, it is of paramount importance to address the problem of pheno-
typic classification when single cells are highly heterogeneous and the number
of cells available is small. Within this context, we have recently proposed the
so-called “Supercell/SVM Paradigm” [30] as a general method for single-cell
phenotyping that focuses on mesoscopic-level emergent properties of groups
of cells. The key contribution of this method is to provide a quantitative
assessment of the critical sample size and number of simultaneous single-cell
13
Figure 5: Analysis of nuclear shapes from images obtained from two normal
and two HGPS cell lines. Probability density distributions for the number
of invaginations of the nuclear boundary corresponding to: (a) single cells
and (b) supercells of size N = 30. Distances to the SVM boundary by
applying machine learning to (c) single cells and (d) supercells of size N = 30,
where 15 parameters per nucleus are used to characterize shape features and
concentration levels of lamin A/C. Adapted from Ref. [30].
measurements needed to identify a phenotype with strong predictive power.
In order to capture emergent behavior, a “supercell of size N” is defined
as the average of the individual measurement vectors of a group of N ran-
domly chosen cells. By repeatedly taking different random subsets of N cells,
“supercell samples” can be built out of the original single-cell datasets; on
these samples, “supercell statistics” can be readily computed. This proce-
dure is illustrated in Fig. 5(a)-(b), where probability density distributions are
shown for one shape parameter (the number of invaginations of the nuclear
boundary) obtained from images from two healthy and two HGPS cell lines.
As mentioned above, HGPS is a premature aging disorder caused by mutant
lamin A that affects the nuclear scaffolding; although HGPS is characterized
by nuclear blebbing, phenotypes at the single-cell level are highly heteroge-
neous (recall Fig. 1(b)). The single-cell distributions in Fig. 5(a) are highly
overlapping, reflecting the fact that, based on individual cells, one is not
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able to distinguish healthy cells from diseased ones. After applying the cell
averaging procedure (using N = 30 randomly selected cells to generate each
supercell), the resulting distributions do not show any significant overlap
between healthy and diseased samples (see Fig. 5(b)). Indeed, the removal
of distribution overlaps is a manifestation of the central limit theorem, by
which distributions of supercells of size N are expected to become narrower
by ∼ 1/
√
N . After cell averaging, machine learning is used to learn what
combination of parameters best distinguishes healthy from diseased cells.
The method implemented in Ref. [30] is a Support Vector Machine (SVM)
with a linear kernel, which is less prone to overfitting issues than nonlinear
mappings [105, 106, 107]. Moreover, the components of the vector normal
to the boundary hyperplane can be straightforwardly interpreted as ampli-
tudes that determine the relative significance of the measured parameters in
achieving class separation. Healthy and HGPS nuclear shapes were charac-
terized by 12 parameters including minor/major axis length, perimeter, area,
tortuosity, mean and standard deviation of the curvature, and the number
of invaginations of the nuclear boundary. Moreover, 3 fluorescence intensity
measurements associated with the concentration of lamin A/C were mea-
sured on each nucleus, thus contributing 3 additional parameters. However,
for single cells, even 15 parameters do not suffice to learn the distinction
between healthy and diseased individual cells. Indeed, Fig. 5(c) shows the
distance from each cell to the SVM boundary, where positive (negative) dis-
tances correspond to the boundary side identified with the healthy (diseased)
class: it is observed that some cells from the healthy cell lines are classified as
diseased, and vice versa. Instead, by applying machine learning to supercell
distributions, 100% classification accuracy is achieved, as shown in Fig. 5(d).
In the analysis of HGPS through nuclear shape measurements, the Su-
percell/SVM method determined that about 30 cells are needed to classify
samples as healthy or diseased, in agreement with usual lab procedures. Be-
sides providing validation of current wet-bench practice, the supercell method
lays out a straightforward framework towards determining how many cells
should be measured in novel scenarios (e.g. drug testing, gene-knockout
phenotypes, etc) where carrying over “tried and tested” rule-of-thumb lab
procedures may be inappropriate.
Let us consider next a more challenging problem, namely that of building
flow-cytometry-based molecular phenotypes for two non-infectious uveitides
(the ocular manifestations of sarcoidosis and Behc¸et’s disease), which are very
difficult to diagnose. By performing 2 scattering and 14 fluorescent measure-
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Figure 6: Jackknife results for sarcoidosis vs Behc¸et’s disease using supercells
of sizeN = 500, where each patient is represented by a cloud of 100 supercells,
as a function of the number of rank-ordered measures used: (a) all cells; (b)
CD8+ T cells. The bars show percentages of correct (green), unclassified
(blue) and incorrect (red) predictions. To the right of each panel, the list of
the top-10 rank-ordered measures is shown. Adapted from Ref. [30].
ments on each cell, samples from 7 sarcoidosis and 6 Behc¸et’s patients were
measured. Since the cohort was small, prediction testing was carried out
by a jackknife (leave-one-out) cross-validation procedure [108]. The SVM
boundary allows one to rank-order the 16 measures from most to least signif-
icant, according to the components of the vector normal to the hyperplane
that separates the two diseases. Thus, one can selectively remove the least
significant measurements from the list and explore the minimal number of
measures needed to correctly predict the class of all (or at least most of) the
samples. Fig. 6 shows jackknife results for supercells of size N = 500, where
each patient is represented by a cloud of 100 supercells, as a function of the
number of rank-ordered measures used. The list of the top 10 measures is
shown to the right of each panel. Fig. 6(a) shows jackknife results based on
all cells, while Fig. 6(b) displays results based on CD8+ T cells, a subpop-
ulation that can be determined by manual gating (CD3+viab−CD8+CD4−)
and typically represents about 5% of the peripheral blood sample. Since
each patient is represented by a cloud of supercells, a prediction was made
only when more than 95% of those supercells lie on any one side of the SVM
boundary. Correct predictions are shown by green bars, incorrect predictions
by red bars, while unclassified samples are shown in blue. While predictions
based on all cells are very poor, for CD8+ T cells no failed predictions are
incurred when five or more measures are used. Therefore, the top five mea-
16
Figure 7: (a) Percentage of correctly classified CD8+ T supercells as a func-
tion of the supercell size and the number of measures used. (b) Linear com-
bination of the top 5 markers IL22, CD3, viability, CD8 and CD62L, as a
function of CD3, for supercells averaged over 500 randomly chosen CD8+ T
cells. Adapted from Ref. [30].
sures listed in Fig. 6(b), if linearly combined as 29% IL22 + 19% CD3 +
18% viab + 17.5% CD8 - 16.5% CD62L, can be used on CD8+ T cells as
molecular phenotypes that distinguish the two diseases.
In Fig. 7(a), the percentage of correctly classified CD8+ T supercells is
shown as a function of the supercell size and the number of measures used.
It turns out that, by using the top five markers, slightly less than 100 cells
are sufficient for reliable prediction. Increasing the number of markers or
averaging over more cells, however, do not significantly change the reliabil-
ity of the classification. The Supercell/SVM framework, thus, allows one
to determine which and how many measures, as well as how many cells,
need to be measured. Because adding markers and measuring larger sam-
ples are expensive and time consuming (and, as mentioned above, might be
strongly constrained by experimental and clinical considerations), the abil-
ity to determine the minimal setup required to build reliable phenotypes is
of paramount importance. Finally, Fig. 7(b) presents a novel visualization
based on the usual 2D scatter plots used in flow cytometry to find cell sub-
populations (recall Fig. 1(a)). By allowing linear combinations of markers
in the vertical axis, a clear separation between disease classes can be readily
observed.
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6 Conclusions
By complementing more traditional approaches based on computational (and,
to a lesser extent, analytical) modeling, data-driven research is opening up
new avenues of investigation fueled by the advent of powerful high-throughput
biomedical technologies. Within that context, this review focuses on cur-
rent efforts towards developing quantitative, unbiased, mathematically ro-
bust methods to learn healthy and diseased phenotypes from multidimen-
sional, single-cell biomedical data.
In order to understand health and disease with multidimensional single-
cell methods, one needs to overcome the challenges arising from the interplay
of complexity, emergence, and cell heterogeneity. Analysis methods based on
multicolor flow cytometry usually rely on rich datasets typically compris-
ing hundreds of thousands (sometimes even millions) of cells. Under such
high-throughput conditions, single-cell-level heterogeneities are often simply
averaged out, thus allowing population-level signatures to emerge. A num-
ber of machine-learning-based classification methods have been developed
recently; they define different kinds of instance spaces, on which machine
learning classifiers are trained and then used to predict on new samples.
For a comparative assessment of the performance and accuracy of different
automated flow cytometry data analysis techniques, see Ref. [50].
High-content image-based phenotyping methods, in turn, usually focus
on pattern recognition and classification of regions of interest. In some cases,
however, image classification and phenotyping relies on pixel tiles that do
not correlate with biologically relevant measures such as cell morphology and
biomarker intensity. Moreover, pattern recognition methods are focused on
pattern classification as opposed to phenotype classification, in the sense that
they typically disregard cell-to-cell heterogeneities within a given phenotype.
For reviews of image-based approaches, see Refs. [54, 57, 73].
In this review, we emphasize the so-called Supercell/SVM paradigm (re-
cently developed by the authors of this review alongside collaborators, see
Ref. [30]) as a unified framework that captures mesoscopic-scale emergence
to build reliable phenotypes. Supercells are multidimensional objects that
represent the collective behavior of groups of cells; within this approach, su-
percells represent the building blocks of healthy and diseased phenotypes.
From a conceptual standpoint, this approach naturally incorporates emer-
gent behavior and thus cell heterogeneity, usually regarded as a roadblock
in the pursuit of characterizing single-cell-level behavior, becomes the funda-
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mental conceptual unit to identify collective phenotypes. From a practical
perspective, furthermore, the Supercell/SVM framework provides a quanti-
tative assessment of the critical sample size and the number of simultaneous
single-cell measurements needed to build a phenotype, which is a key piece of
information given the fact that, in many single-cell applications, the number
of measured cells and the number of measurements per cell are severely lim-
ited due to a variety of constraints, such as experimental costs, technological
capabilities, specimen collection procedures, the availability of specialized
personnel, and others.
Finally, let us point out the importance of interdisciplinary exchanges of
methods and ideas such as these, in which tools and concepts from statistical
physics, data mining, and mathematics are successfully applied to the most
pressing problems in the life sciences. We hope that the powerful synergy of
collaborative efforts across disciplines grows ever stronger and bears fruit by
improving diagnosis, prognosis, and decision making in the clinical realm.
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